Alterity Therapeutics (PRNAD) Cash from Operations (2009 - 2020)

Alterity Therapeutics (PRNAD) has reported Cash from Operations for 9 consecutive years, with 6181351.89 the latest figure, recorded in Q2 2020.

• In Q2 2020, Cash from Operations rose 36.76% year-over-year to 6181351.89; the TTM figure through Jun 2020 stood at 19370713.16 (down 21.79% YoY), while the FY2025 annual figure was 7333759.44, up 11.72% from the prior year.
• Cash from Operations came in at 6181351.89 for Q2 2020 at Alterity Therapeutics, down from 1766470.98 in the prior quarter.
• The five-year high for Cash from Operations was 1766470.98 in Q4 2019, with the low at 9774963.11 in Q2 2019.
• Average Cash from Operations over 5 years is 3414551.96, with a median of 4405908.68 recorded in 2017.
• The largest YoY upside for Cash from Operations was 134.1% in 2019 against a maximum downside of 20575.33% in 2019.
• Year by year, Cash from Operations stood at 465813.11 in 2016, then slumped by 93.6% to 901823.06 in 2017, then plunged by 474.49% to 5180869.14 in 2018, then soared by 134.1% to 1766470.98 in 2019, then sank by 449.93% to 6181351.89 in 2020.
• According to Business Quant data, Cash from Operations over the past three periods registered 6181351.89, 1766470.98, and 9774963.11 for Q2 2020, Q4 2019, and Q2 2019 respectively.